Andy Yeung

Andy Yeung is passionate about carrying out innovative drug design and research to deliver more effective immunotherapy drugs to patients. He brings extensive experience in the biopharmaceutical industry, focusing on discovery and development. Andy co-founded Asher Bio in 2019 and currently serves as the C.T.O. and Board observer of Asher Bio, responsible for initiating drug concepts and leading the engineering and technology development of antibody and cytokine candidates.

Previously Andy spent ten years at Pfizer, most recently holding the title, Director or Biotherapeutic Design and Discovery. Andy led protein engineering efforts for programs in metabolic diseases, ophthalmology, infectious diseases, and oncology (CD3 bispecific, CAR-T, immune-oncology antibodies, and cytokines). Andy's work directly led to five preclinical research projects advancing through IND-enabling development into the clinic.

Prior to Pfizer, Andy spent four years in the Antibody Engineering Department at Genentech as a postdoctoral fellow. He has published numerous articles in peer-reviewed journals and is an inventor on 15 issued patents and patent applications. He received his Ph.D. in Chemical engineering and M.S. in Chemical Engineering Practice from the Massachusetts Institute of technology and a B.SC. In Chemical Engineering from the University of Wisconsin-Madison.